8-K: Danimer Scientific Files for Chapter 11 Bankruptcy Protection

Danimer Scientific and its subsidiaries have filed for Chapter 11 bankruptcy to facilitate an orderly winddown and potential sale of assets.

Summary

• Danimer Scientific, Inc. and its subsidiaries filed voluntary petitions for Chapter 11 bankruptcy on March 18, 2025.
• The company intends to operate as debtors in possession while seeking to sell its manufacturing facilities.
• Danimer Scientific is seeking court approval for a debtor-in-possession (DIP) facility of up to $3 million in new money loans, plus $12 million rolled-up from an existing note.
• The DIP facility will fund the winddown of operations, payroll for remaining employees, and general corporate needs.
• The company is also seeking approval for procedures to protect its net operating losses (NOLs) by restricting transactions involving substantial stockholders (owning at least 4.5% of common stock) and 50-percent shareholders.
• The bankruptcy filing triggered the acceleration of approximately $400.8 million in outstanding debt.
• Trading in the company's securities is considered highly speculative, and shareholders could experience a significant or complete loss.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the bankruptcy filing, significant debt acceleration, and potential loss for shareholders. The company is in a distressed situation.

Positives

• The DIP facility will allow the company to fund its winddown operations and maintain key employee payroll.
• The company is actively seeking a buyer for its manufacturing facilities.
• The NOL Motion aims to preserve the value of the company's tax attributes.

Negatives

• The company has filed for Chapter 11 bankruptcy protection.
• The bankruptcy filing triggered the acceleration of approximately $400.8 million in outstanding debt.
• Shareholders could experience a significant or complete loss on their investment.
• Trading in the company's securities is considered highly speculative.

Risks

• The company's ability to fund its planned operations and continue as a going concern is uncertain.
• The Chapter 11 cases could have an adverse impact on the company's business, financial condition, and results of operations.
• The company's ability to maintain relationships with customers, employees, and other third parties is at risk.
• The company's ability to obtain court approvals is not guaranteed.
• The length of time the company will operate under Chapter 11 protection is uncertain.
• There are risks associated with third-party motions in the Chapter 11 Cases.

Future Outlook

The company will operate as debtors in possession while seeking to sell its manufacturing facilities and wind down operations.

Industry Context

The bankruptcy filing reflects challenges in the bioplastics industry, potentially due to factors such as production costs, market adoption rates, and competition from traditional plastics.

Comparison to Industry Standards

• It is difficult to compare Danimer Scientific's situation directly to industry standards without more information on the specific reasons for the bankruptcy.
• However, other companies in the bioplastics space, such as NatureWorks and Corbion, have focused on scaling production and securing partnerships to drive growth.
• The success of these companies depends on factors such as technological innovation, cost competitiveness, and regulatory support for bioplastics.

Stakeholder Impact

• Shareholders could experience a significant or complete loss on their investment.
• Employees face uncertainty regarding their jobs.
• Customers and suppliers may be affected by the winddown of operations.
• Creditors face the risk of not recovering the full amount of their claims.

Next Steps

• The company will seek court approval for the DIP facility and the NOL Motion.
• The company will continue to operate as debtors in possession.
• The company will pursue a sale process for its manufacturing facilities.

Key Dates